Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Puma Biotechnology (NQ: PBYI )

5.035 +0.155 (+3.18%)
Streaming Delayed Price Updated: 10:13 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Puma Biotechnology

< Previous 1 2 3 4 Next >
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Releases Updated Corporate Presentation
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Third Quarter 2021 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Second Quarter 2021 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports First Quarter 2021 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.